Supply Chain
-
CMMI, Drug Prices, Drug shortages, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Supply ChainAMP is WAC — 10/17/25
Read more: AMP is WAC — 10/17/25Caught my Eye Cool Idea, But. The Food and Drug Administration (FDA) puts announced a new pilot prioritization program for the review of Abbreviated New Drug Applications (ANDAs) to support generic manufacturing in the U.S. I mean it sounds good, except… there are three criteria for applicants: Only 9% of API manufacturers are in the…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, DTC, Employers, Medicare Advantage, Medicare Part D, Reference Pricing, Supply Chain, Utilization ManagementAMP is WAC — 9/12/25
Read more: AMP is WAC — 9/12/25On one hand, a busy week in the world of health policy. The quicksand of news in 2025 is real so I do my best to sidestep some news (MAHA report) to dive into the things that I think are important for my clients – including expected premium spikes, 340B rebate backlash and Medicare changes.…
-
AMP is WAC — 8/29/25
Read more: AMP is WAC — 8/29/25It felt like a relatively quiet week. Or did I just completely jinx today? Caught my Eye Ask Me Anything. FAQs released on the 340B Model Pilot program. This is the program where manufacturers with 2026 Medicare negotiated drugs can move to a rebate program for 340B for the negotiated drugs. Manufacturers that submit plans…
-
Inflation Reduction Act, Medicare Advantage, Medicare Part D, Reference Pricing, State-based Reform, Supply Chain, VaccinesAMP is WAC — 8/15/25
Read more: AMP is WAC — 8/15/25Caught my Eye Surely a Coincidence. President Trump called for direct to consumer purchasing at Most Favored Nation Pricing and BlinkRx said that they could offer this service. Donald Trump Jr. is on their board. Lobby Me This. Stat News had an article about a new coalition, IRA Watch, that is formed to discuss…
-
340B, Caught my eye, Drug shortages, Pharmacy Benefit Managers, Supply Chain, Utilization ManagementAMP is WAC — 7/25/25
Read more: AMP is WAC — 7/25/25Next week we’ll have our first glimpse of the Medicare Part D premiums for 2026; I expect them to be pretty awful. The Part D redesign shifted additional liability onto plans without changing enough of the premium calculation. Some articles next week will say it is unintended consequence; I think it is an intended one…
-
Biosimilars, Caught my eye, Drug Prices, Drug shortages, ICER, Inflation Reduction Act, Medicare Advantage, Medicare Part D, Obesity, Supply Chain, ValueCaught my eye — 4/11/25
Read more: Caught my eye — 4/11/25Some days I sit down the pottery wheel and I pull 4 bowls or vases in a row that are fantastic. Other days (like, oh, this Sunday and Wednesday) it all collapses. Here is hoping that all of us get better at staying centered and not collapsing. I’d Prefer Not. The 2026 Medicare Advantage and…
-
Caught my eye — 2/28/25
Read more: Caught my eye — 2/28/25Tariffic. This week Eli Lilly announced they were investing at least $27 billion in US manufacturing, which is pretty cool. Was it to buy favor with the new Administration? It certainly does not hurt. I get the allure of manufacturing in the United States. If a country wanted to hurt us, they could stop sending…
Latest news
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
- AMP is WAC — 2/6/26
Categories
- 340B (62)
- Affordable Care Act (21)
- Alzheimer's (10)
- Biosimilars (31)
- Caught my eye (101)
- Cell and Gene (5)
- Chevron Deference (2)
- CMMI (26)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (6)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (67)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (76)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (26)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)